Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$130000.0.

  • Lineage Cell Therapeutics' Change in Receivables fell 17692.31% to -$130000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$278000.0, marking a year-over-year decrease of 71764.71%. This contributed to the annual value of -$106000.0 for FY2024, which is 12376.68% down from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Change in Receivables is -$130000.0, which was down 17692.31% from $43000.0 recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Change in Receivables high stood at $753000.0 for Q4 2021, and its period low was -$50.3 million during Q1 2022.
  • In the last 5 years, Lineage Cell Therapeutics' Change in Receivables had a median value of $43000.0 in 2025 and averaged -$2.6 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first plummeted by 3737481.48% in 2022, then skyrocketed by 291666.67% in 2024.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Change in Receivables stood at $753000.0 in 2021, then crashed by 114.34% to -$108000.0 in 2022, then skyrocketed by 382.41% to $305000.0 in 2023, then fell by 23.61% to $233000.0 in 2024, then plummeted by 155.79% to -$130000.0 in 2025.
  • Its Change in Receivables was -$130000.0 in Q3 2025, compared to $43000.0 in Q2 2025 and -$424000.0 in Q1 2025.